US biotech company Generex has announced that the Canadian Intellectual Property Office has granted its patent titled "Pharmaceutical Compositions for Buccal and Pulmonary Application." Generex develops formulations for buccal delivery using its RapidMist metered dose device, which is essentially an MDI designed to deliver aerosol to the oral cavity instead of to the lungs. Read the company’s press release.
